Cellosaurus logo
expasy logo

Cellosaurus A-375 (CVCL_0132)

[Text version]
Cell line name A-375
Synonyms A 375; A375; A375-MEL; A375-mel; A375mel
Accession CVCL_0132
Resource Identification Initiative To cite this cell line use: A-375 (RRID:CVCL_0132)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: MD Anderson Cell Lines Project.
Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
Population: Caucasian.
Doubling time: 26.9 +- 6.9 hours (PubMed=29275043); ~32 hours (PBCF).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: Deep phosphoproteome analysis.
Omics: Deep proteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: Proteome analysis by 2D-DE/MS.
Omics: Secretome proteome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Misspelling: A-735; Note=Occasionally.
Derived from site: In situ; Skin; UBERON=UBERON_0002097.
Sequence variations
  • Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=12068308; PubMed=15467732; PubMed=26405815; PubMed=29492214; ATCC=CRL-1619; Cosmic-CLP=906793; DepMap=ACH-000219).
  • Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (PubMed=29492214; ATCC=CRL-1619; Cosmic-CLP=906793; DepMap=ACH-000219).
  • Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (PubMed=29492214; ATCC=CRL-1619; Cosmic-CLP=906793; DepMap=ACH-000219).
  • Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
HLA typing Source: PubMed=77569
Class I

Source: PubMed=25960936
Class I
Class II

Source: PubMed=26589293
Class I
Class II
Genome ancestry Source: PubMed=30894373

Origin% genome
Native American0.49
East Asian, North1.69
East Asian, South0
South Asian0
European, North67.22
European, South29.75
Disease Amelanotic melanoma (NCIt: C3802)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_6546 (4-1.10)CVCL_UD29 (A-375 KRAS p.G13D)CVCL_UD28 (A-375 MEK1 p.Q56P)
CVCL_JF22 (A-375 NRAS p.Q61K)CVCL_C8WV (A-375-Luc)CVCL_LC86 (A375 NRAS (Q61K/+/+))
CVCL_C3D8 (A375 NY-ESO-1 Knockout)CVCL_C0Q6 (A375 PLX/AZD-resistant)CVCL_C3EX (A375 Safe Harbor Landing Pad)
CVCL_C4RR (A375 XPA-mutated clone A3)CVCL_C4RS (A375 XPA-mutated clone A9)CVCL_C4RT (A375 XPA-mutated clone B1)
CVCL_2294 (A375-C5)CVCL_2295 (A375-C6)CVCL_QZ67 (A375-eGFP-Puro)
CVCL_C8YB (A375-ER-2)CVCL_QZ68 (A375-Fluc-Neo/eGFP-Puro)CVCL_QZ69 (A375-Fluc-Neo/hNIS-Puro)
CVCL_QZ70 (A375-Fluc-Puro)CVCL_QZ71 (A375-hNIS-Neo/eGFP-Puro)CVCL_QZ72 (A375-hNIS-Puro)
CVCL_QZ73 (A375-iRFP-Neo)CVCL_QZ74 (A375-iRFP-Neo/Fluc-Puro)CVCL_QZ75 (A375-iRFP-Neo/hNIS-Puro)
CVCL_B7NR (A375-Luc-RFP)CVCL_UR32 (A375-Luc2)CVCL_B222 (A375-M)
CVCL_X494 (A375-MA1)CVCL_C7GI (A375-NTP-R)CVCL_6233 (A375-P)
CVCL_6234 (A375-R)CVCL_A2CR (A375-R1)CVCL_A1VP (A375-RMR)
CVCL_5649 (A375-SM)CVCL_AP96 (A375-VR [2014])CVCL_AQ00 (A375-VR [2015])
CVCL_0136 (A375.S2)CVCL_IW10 (A375/R)CVCL_R745 (A375PF11)
CVCL_Y439 (A375S1)CVCL_XE59 (A375sci)CVCL_B0ZF (Abcam A-375 IL13RA2 KO)
CVCL_B7V4 (Abcam A-375 NT5E KO)CVCL_KS59 (CellSensor AP1-bla A375)CVCL_KS16 (CellSensor SBE-bla A375)
CVCL_6286 (DRO)CVCL_D6AF (HyCyte A375 KO-hSETD2)CVCL_ZJ05 (LanthaScreen ERK2 A375)
Sex of cell Female
Age at sampling 54Y
Category Cancer cell line
STR profile Source(s): AddexBio=C0020004/4992; ATCC=CRL-1619; CCRID; CLS=300110; Cosmic-CLP=906793; ECACC=88113005; Technion Genomics Center BCF; IZSLER=BS TCL 88; PubMed=25056119; PubMed=25877200

Penta D9,15
Penta E10,12

Run an STR similarity search on this cell line
Web pages https://www.synapse.org/#!Synapse:syn31544560

PubMed=4357758; DOI=10.1093/jnci/51.5.1417
Giard D.J., Aaronson S.A., Todaro G.J., Arnstein P., Kersey J.H., Dosik H., Parks W.P.
In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors.
J. Natl. Cancer Inst. 51:1417-1423(1973)

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

Bruggen J., Sorg C., Macher E.
Membrane associated antigens of human malignant melanoma V: Serological typing of cell lines using antisera from nonhuman primates.
Cancer Immunol. Immunother. 5:53-62(1978)

PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x
Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.
Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique.
Tissue Antigens 11:279-286(1978)

PubMed=375235; DOI=10.1073/pnas.76.3.1288
Sherwin S.A., Sliski A.H., Todaro G.J.
Human melanoma cells have both nerve growth factor and nerve growth factor-specific receptors on their cell surfaces.
Proc. Natl. Acad. Sci. U.S.A. 76:1288-1292(1979)

PubMed=22282976; DOI=10.1093/carcin/1.1.21
Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A., Mattern M.R.
Human tumor cell strains defective in the repair of alkylation damage.
Carcinogenesis 1:21-32(1980)

Bruggen J., Macher E., Sorg C.
Expression of surface antigens and its relation to parameters of malignancy in human malignant melanoma.
Cancer Immunol. Immunother. 10:121-127(1981)

PubMed=6954533; DOI=10.1073/pnas.79.7.2194
Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A., Aaronson S.A., Wong-Staal F.
Differential expression of the amv gene in human hematopoietic cells.
Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982)

Dracopoli N.C., Fogh J.
Polymorphic enzyme analysis of cultured human tumor cell lines.
J. Natl. Cancer Inst. 70:469-476(1983)

PubMed=6500159; DOI=10.1159/000163283
Gershwin M.E., Lentz D., Owens R.B.
Relationship between karyotype of tissue culture lines and tumorigenicity in nude mice.
Exp. Cell Biol. 52:361-370(1984)

PubMed=6584666; DOI=10.1093/jnci/72.4.913
Kozlowski J.M., Hart I.R., Fidler I.J., Hanna N.
A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mice.
J. Natl. Cancer Inst. 72:913-917(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=1832891; DOI=10.1016/0277-5379(91)90277-K
Hansson J., Fichtinger-Schepman A.M.J., Edgren M.R., Ringborg U.
Comparative study of two human melanoma cell lines with different sensitivities to mustine and cisplatin.
Eur. J. Cancer 27:1039-1045(1991)

PubMed=9670966; DOI=10.4049/jimmunol.161.2.877
Bettinotti M.P., Kim C.J., Lee K.-H., Roden M., Cormier J.N., Panelli M.C., Parker K.K., Marincola F.M.
Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
J. Immunol. 161:877-889(1998)

PubMed=9973934; DOI=10.1016/S0165-4608(98)00122-8
Nelson M.A., Ariza M.E., Yang J.-M., Thompson F.H., Taetle R., Trent J.M., Wymer J., Massey-Brown K.S., Broome-Powell M., Easton J., Lahti J.M., Kidd V.J.
Abnormalities in the p34cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanoma.
Cancer Genet. Cytogenet. 108:91-99(1999)

PubMed=10497214; DOI=10.1074/jbc.274.40.28505
Ariza M.E., Broome-Powell M., Lahti J.M., Kidd V.J., Nelson M.A.
Fas-induced apoptosis in human malignant melanoma cell lines is associated with the activation of the p34(cdc2)-related PITSLRE protein kinases.
J. Biol. Chem. 274:28505-28513(1999)

PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)

PubMed=14871852; DOI=10.1158/0008-5472.CAN-03-2209
Hogan K.T., Coppola M.A., Gatlin C.L., Thompson L.W., Shabanowitz J., Hunt D.F., Engelhard V.H., Ross M.M., Slingluff C.L. Jr.
Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanoma.
Cancer Res. 64:1157-1163(2004)

PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x
Tsao H., Goel V., Wu H., Yang G., Haluska F.G.
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
J. Invest. Dermatol. 122:337-341(2004)

PubMed=15467732; DOI=10.1038/sj.onc.1208152
Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J., Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.
Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
Oncogene 23:8796-8804(2004)

PubMed=17308088; DOI=10.1158/0008-5472.CAN-06-3311
Shields J.M., Thomas N.E., Cregger M., Berger A.J., Leslie M., Torrice C., Hao H.-L., Penland S., Arbiser J.L., Scott G.A., Zhou T., Bar-Eli M., Bear J.E., Der C.J., Kaufmann W.K., Rimm D.L., Sharpless N.E.
Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma.
Cancer Res. 67:1502-1512(2007)

PubMed=18172304; DOI=10.1158/0008-5472.CAN-07-1939
Sabatino M., Zhao Y.-D., Voiculescu S., Monaco A., Robbins P.F., Karai L., Nickoloff B.J., Maio M., Selleri S., Marincola F.M., Wang E.
Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis.
Cancer Res. 68:122-131(2008)

PubMed=19727395; DOI=10.1371/journal.pone.0006888
Wadlow R.C., Wittner B.S., Finley S.A., Bergquist H., Upadhyay R., Finn S.P., Loda M., Mahmood U., Ramaswamy S.
Systems-level modeling of cancer-fibroblast interaction.
PLoS ONE 4:E6888-E6888(2009)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=21343389; DOI=10.1158/0008-5472.CAN-10-2958
Rose A.E., Poliseno L., Wang J.-H., Clark M., Pearlman A., Wang G.-M., Vega y Saenz de Miera E.C., Medicherla R., Christos P.J., Shapiro R., Pavlick A., Darvishian F., Zavadil J., Polsky D., Hernando E., Ostrer H., Osman I.
Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression.
Cancer Res. 71:2561-2571(2011)

PubMed=21424129; DOI=10.3892/or.2011.1220
Manca A., Sini M.C., Izzo F., Ascierto P.A., Tatangelo F., Botti G., Gentilcore G., Capone M., Mozzillo N., Rozzo C., Cossu A., Tanda F., Palmieri G.
Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.
Oncol. Rep. 25:1495-1502(2011)

PubMed=21673604; DOI=10.1097/CMR.0b013e32834495c3
Orgaz J.L., Benguria A., Sanchez-Martinez C., Ladhani O., Volpert O.V., Jimenez B.
Changes in the gene expression profile of A375 human melanoma cells induced by overexpression of multifunctional pigment epithelium-derived factor.
Melanoma Res. 21:285-297(2011)

PubMed=21857157; DOI=10.4161/cc.10.17.17068
Caputo E., Maiorana L., Vasta V., Pezzino F.M., Sunkara S., Wynne K., Elia G., Marincola F.M., McCubrey J.A., Libra M., Travali S., Kane M.
Characterization of human melanoma cell lines and melanocytes by proteome analysis.
Cell Cycle 10:2924-2936(2011)

PubMed=22178978; DOI=10.1016/j.freeradbiomed.2011.11.019
Swalwell H., Latimer J., Haywood R.M., Birch-Machin M.A.
Investigating the role of melanin in UVA/UVB- and hydrogen peroxide-induced cellular and mitochondrial ROS production and mitochondrial DNA damage in human melanoma cells.
Free Radic. Biol. Med. 52:626-634(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23039341; DOI=10.1186/1476-4598-11-75
Byron S.A., Loch D.C., Wellens C.L., Wortmann A., Wu J.-Y., Wang J., Nomoto K., Pollock P.M.
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.
Mol. Cancer 11:75.1-75.15(2012)

PubMed=24581590; DOI=10.1016/j.jdermsci.2014.01.006
Gehrke S., Otsuka A., Huber R., Meier B., Kistowska M., Fenini G., Cheng P., Dummer R., Kerl K., Contassot E., French L.E.
Metastatic melanoma cell lines do not secrete IL-1beta but promote IL-1beta production from macrophages.
J. Dermatol. Sci. 74:167-169(2014)

PubMed=25056119; DOI=10.1158/0008-5472.CAN-14-1232-T
Watson I.R., Li L.-R., Cabeceiras P.K., Mahdavi M., Gutschner T., Genovese G., Wang G.-C., Fang Z.-N., Tepper J.M., Stemke-Hale K., Tsai K.Y., Davies M.A., Mills G.B., Chin L.
The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.
Cancer Res. 74:4845-4852(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26405815; DOI=10.1371/journal.pone.0138210
Capaldo B.J., Roller D.G., Axelrod M.J., Koeppel A.F., Petricoin E.F. III, Slingluff C.L. Jr., Weber M.J., Mackey A.J., Gioeli D., Bekiranov S.
Systems analysis of adaptive responses to MAP kinase pathway blockade in BRAF mutant melanoma.
PLoS ONE 10:E0138210-E0138210(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=26673621; DOI=10.18632/oncotarget.6548
Roller D.G., Capaldo B.J., Bekiranov S., Mackey A.J., Conaway M.R., Petricoin E.F. III, Gioeli D., Weber M.J.
Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.
Oncotarget 7:2734-2753(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29275043; DOI=10.1016/j.jprot.2017.12.013
Liberato T., Pessotti D.S., Fukushima I., Kitano E.S., Serrano S.M.T., Zelanis A.
Signatures of protein expression revealed by secretome analyses of cancer associated fibroblasts and melanoma cell lines.
J. Proteomics 174:1-8(2018)

PubMed=29492214; DOI=10.18632/oncotarget.23989
Sini M.C., Doneddu V., Paliogiannis P., Casula M., Colombino M., Manca A., Botti G., Ascierto P.A., Lissia A., Cossu A., Palmieri G.
Genetic alterations in main candidate genes during melanoma progression.
Oncotarget 9:8531-8541(2018)

PubMed=29605720; DOI=10.1016/j.neo.2018.02.009
Mologni L., Costanza M., Sharma G.G., Viltadi M., Massimino L., Citterio S., Purgante S., Raman H., Pirola A., Zucchetti M., Piazza R., Gambacorti-Passerini C.
Concomitant BCORL1 and BRAF mutations in vemurafenib-resistant melanoma cells.
Neoplasia 20:467-477(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=35128241; DOI=10.1021/acsomega.1c05361
Martinez R. III, Huang W.-L., Buck H., Rea S., Defnet A.E., Kane M.A., Shapiro P.
Proteomic changes in the monolayer and spheroid melanoma cell models of acquired resistance to BRAF and MEK1/2 inhibitors.
ACS Omega 7:3293-3311(2022)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cell line collections (Providers) Abcam; ab275461
AddexBio; C0020004/4992
ATCC; CRL-1619
ATCC; CRL-7904 - Discontinued
BCRC; 60039
BCRJ; 0278
CLS; 300110
ECACC; 88113005
IBRC; C10141
KCB; KCB 99003YJ
NCBI_Iran; C136
Ubigene; YC-C036
Cell line databases/resources CLO; CLO_0001544
CLO; CLO_0001581
CLO; CLO_0001582
MCCL; MCC:0000024
CLDB; cl198
CLDB; cl199
cancercelllines; CVCL_0132
CCRID; 1101HUM-PUMC000126
CCRID; 1101HUM-PUMC000327
Cell_Model_Passport; SIDM00795
CGH-DB; 9313-4
Cosmic-CLP; 906793
DepMap; ACH-000219
IGRhCellID; A375
LINCS_HMS; 50060
Lonza; 970
Anatomy/cell type resources BTO; BTO:0002806
Biological sample resources BioSample; SAMN03472142
BioSample; SAMN05292441
BioSample; SAMN07709998
BioSample; SAMN07709999
BioSample; SAMN07710000
BioSample; SAMN07710001
BioSample; SAMN07710002
BioSample; SAMN07710003
BioSample; SAMN07710004
BioSample; SAMN10988347
CRISP screens repositories BioGRID_ORCS_Cell_line; 44
Chemistry resources ChEMBL-Cells; CHEMBL3308077
ChEMBL-Targets; CHEMBL613859
GDSC; 906793
PharmacoDB; A375_42_2019
PubChem_Cell_line; CVCL_0132
Encyclopedic resources Wikidata; Q54605986
Experimental variables resources EFO; EFO_0002103
Gene expression databases ArrayExpress; E-MTAB-38
ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM206443
GEO; GSM218051
GEO; GSM274681
GEO; GSM276771
GEO; GSM555121
GEO; GSM555173
GEO; GSM827158
GEO; GSM886854
GEO; GSM887919
GEO; GSM952580
GEO; GSM1092559
GEO; GSM1138787
GEO; GSM1177892
GEO; GSM1177893
GEO; GSM1374382
GEO; GSM1669582
GEO; GSM1671962
GEO; GSM1671967
GEO; GSM1671977
GEO; GSM1671981
GEO; GSM1671982
GEO; GSM1671987
GEO; GSM1671990
GEO; GSM1672001
GEO; GSM1672004
GEO; GSM1672007
GEO; GSM1672011
GEO; GSM1672017
GEO; GSM1672024
GEO; GSM1672027
GEO; GSM1672030
GEO; GSM1672039
GEO; GSM1672051
GEO; GSM1672062
GEO; GSM1672067
GEO; GSM1672078
GEO; GSM1672097
GEO; GSM1672102
GEO; GSM1672119
GEO; GSM1672135
GEO; GSM3039510
GEO; GSM3039516
GEO; GSM3039517
GEO; GSM3039518
Polymorphism and mutation databases Cosmic; 686480
Cosmic; 687431
Cosmic; 706114
Cosmic; 876698
Cosmic; 888861
Cosmic; 897482
Cosmic; 897735
Cosmic; 905226
Cosmic; 906793
Cosmic; 928688
Cosmic; 933003
Cosmic; 1006556
Cosmic; 1022280
Cosmic; 1054855
Cosmic; 1132587
Cosmic; 1155278
Cosmic; 1211162
Cosmic; 1303032
Cosmic; 1458961
Cosmic; 1459655
Cosmic; 1477406
Cosmic; 1481413
Cosmic; 1507620
Cosmic; 1537486
Cosmic; 1555009
Cosmic; 1669118
Cosmic; 1812178
Cosmic; 1888914
Cosmic; 1890486
Cosmic; 1989294
Cosmic; 1995332
Cosmic; 2036699
Cosmic; 2230112
Cosmic; 2233660
Cosmic; 2479252
Cosmic; 2791113
IARC_TP53; 21163
LiGeA; CCLE_226
Progenetix; CVCL_0132
Proteomic databases PRIDE; PXD001485
PRIDE; PXD004343
PRIDE; PXD005912
PRIDE; PXD007265
PRIDE; PXD021877
PRIDE; PXD022992
PRIDE; PXD025255
PRIDE; PXD025881
PRIDE; PXD026952
PRIDE; PXD027886
PRIDE; PXD028863
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001000978
EGA; EGAS00001002554
Entry history
Entry creation04-Apr-2012
Last entry update02-May-2024
Version number46